Event / FDA#330tier 2experimental liveNew

adcomm split vote short

cadence: Dailydata: mediumshort only
paper
2010
Source
Carpenter, D., Chattopadhyay, J., Moffitt, S. & Nall, C. (2010). "The Complications of Controlling Agency Time Discretion: FDA Review Deadlines and Postmarket Drug Safety." American Political Science Review, 105(4), 644-666.
Read the paper →

What it checks

When a drug's FDA review keeps getting delayed (3+ different target dates), we short the sponsor for the next 1-2 months.

Mechanism

Contested FDA AdComm reviews (split votes, e.g. 7-6) predict final-PDUFA rejection more often than baseline; sponsor stock drifts negative 30-60d before action date.

No production champion data for this family yet. Stats appear once the discovery pipeline promotes at least one strategy with this family tag, or once a multi-family blend that includes it earns a champion slot.

Signal rule

Drug crosses >=3 distinct PDUFA action-date revisions in fda_adcomm (contested-review proxy) -> SHORT sponsor T+1; hold 30/60 trading days.

Data dependencies

  • daily_prices

    Adjusted-close OHLCV for every US-listed ticker; primary price feed.

  • fda_adcomm

    Worker data table — see services/worker schema.

Expected edge

Paper alpha
above-baseline rejection
Paper window
T+1 to T+60d

Carpenter et al 2010: above-baseline rejection rate on contested reviews.

Example tickers where this is likely to fire

Illustrative only — the signal fires based on the live data, not a fixed list.

Related families

Explore adcomm split vote short on alphactor.ai

See which tickers this family is currently firing on, with live signals and rankings.

For informational and educational purposes only. Not financial advice. Learn more